Puma Biotechnology - PBYI Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PBYI shares.
View PBYI analyst ratings or view top-rated stocks.

1 brokers have issued 12-month price objectives for Puma Biotechnology's shares. Their PBYI share price forecasts range from $8.00 to $8.00. On average, they expect the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 241.9% from the stock's current price.
View analysts price targets for PBYI or view top-rated stocks among Wall Street analysts.

Puma Biotechnology's stock was trading at $4.23 at the beginning of the year. Since then, PBYI shares have decreased by 44.7% and is now trading at $2.34.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our PBYI earnings forecast.

Puma Biotechnology, Inc. (NASDAQ:PBYI) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.78. The biopharmaceutical company earned $46.20 million during the quarter, compared to analyst estimates of $53.44 million. The company's revenue for the quarter was down 9.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.79) EPS.

Puma Biotechnology updated its first quarter 2023 earnings guidance on Thursday, March, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $47.00 million-$52.00 million, compared to the consensus revenue estimate of $51.00 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Puma Biotechnology's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (5.87%), Renaissance Technologies LLC (3.72%), Globeflex Capital L P (1.23%), Morgan Stanley (1.09%), Rice Hall James & Associates LLC (0.84%) and Geode Capital Management LLC (0.83%). Insiders that own company stock include Alan H Auerbach, Alvin F Wong, Ann Calby Miller, Douglas M Hunt, Jay M Moyes, Langley Steinert, Maximo F Nougues, Michael Patrick Miller, Richard Paul Bryce and Troy Edward Wilson.
View institutional ownership trends.

Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PBYI stock can currently be purchased for approximately $2.34.

Puma Biotechnology (NASDAQ:PBYI) has a market capitalization of $109.14 million and generates $228 million in revenue each year.

The company employs 196 workers across the globe.

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The official website for the company is www.pumabiotechnology.com. The biopharmaceutical company can be reached via phone at (424) 248-6500, via email at ir@pumabiotechnology.com, or via fax at 424-248-6501.